Cancer Immunotherapy: Comprehensive Mechanism Analysis of Mesoporous‐Silica‐Nanoparticle‐Induced Cancer Immunotherapy (Adv. Healthcare Mater. 10/2016)

Wang, Xiupeng; Li, Xia; Yoshiyuki, Kazuko; Watanabe, Yohei; Sogo, Yu; Ohno, Tadao; Tsuji, Noriko M.; Ito, Atsuo

doi:10.1002/adhm.201670051

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The neoantigen-adjuvant vaccines and the neoantigen-pulsed DC vaccines were prepared for individualized tumor treatments. On one hand, peptide vaccines have the advantages of simple synthesis, economical production, and clinical safety; on the other hand, peptide vaccines have two major shortcomings: low immunogenicity and MHC restriction [6]. Hence, currently, the most common solution is to add an immunological adjuvant, which is essential for inducing an effective immune response [28].…”

Section: Discussionmentioning

confidence: 99%

“…Peptide vaccines have been extensively studied, because they are simple, safe, and economical [4]. However, due to their unique peptide epitopes, low molecular weights, easy degradation, and short half-lives, peptide vaccines have two basic limitations: low immunogenicity and major histocompatibility complex (MHC) restriction [5,6]. Therefore, adding immunological adjuvants to peptide vaccines is essential to induce an effective immune response [7].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Zhang¹,

Yuan²,

Shu³

et al. 2019

Cancer Immunol Immunother

View full text Add to dashboard Cite

Development of personalized cancer vaccines based on neoantigens has become a new direction in cancer immunotherapy. Two forms of cancer vaccines have been widely studied: tumor-associated antigen (including proteins, peptides, or tumor lysates)-pulsed dendritic cell (DC) vaccines and protein-or peptide-adjuvant vaccines. However, different immune modalities may produce different therapeutic effects and immune responses when the same antigen is used. Therefore, it is necessary to choose a more effective neoantigen vaccination method. In this study, we compared the differences in immune and anti-tumor effects between neoantigen-pulsed DC vaccines and neoantigen-adjuvant vaccines using murine lung carcinoma (LL2) candidate neoantigens. The enzyme-linked immunospot (ELISPOT) assay showed that 4/6 of the neoantigen-adjuvant vaccines and 6/6 of the neoantigen-pulsed DC vaccines induced strong T-cell immune responses. Also, 2/6 of the neoantigen-adjuvant vaccines and 5/6 of the neoantigen-pulsed DC vaccines exhibited potent anti-tumor effects. The results indicated that the neoantigen-pulsed DC vaccines were superior to the neoantigen-adjuvant vaccines in both activating immune responses and inhibiting tumor growth. Our fundings provide an experimental basis for the selection of immune modalities for the use of neoantigens in individualized tumor immunotherapies.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Zhang¹,

Yuan²,

Shu³

et al. 2019

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…During recent years where the use of engineered nanoparticles has increased rapidly, silica nanoparticles have become one of the most commonly used nanomaterials in amongst others, biomedical research as a result of several benefits including biocompatibility, stability, and low production costs [11]. As an example, the field of cancer immunotherapy increasingly looks into the use of amorphous silica as immunoadjuvant to treat cancer in humans [12,13,14]. Despite their common and increased use, cytotoxic effects have been reported [15,16].…”

Section: Introductionmentioning

confidence: 99%

Cellular Responses of Industrially Relevant Silica Dust on Human Glial Cells In Vitro

Arnoldussen

Ervik

Eriksen

et al. 2019

IJMS

View full text Add to dashboard Cite

Despite the rigorous emission control measures in the ferroalloy industry, there are still emissions of dust during the production of various alloys. Dust particles were collected from laboratory scale processes where oxide particulate matter was formed from liquid silicon (metallurgical grade). The dust was produced in a dry air atmosphere to mimic industrial conditions. To investigate possible effects of ultrafine dust on the central nervous system, a human astrocytic cell line was employed to investigate inflammatory effects of particles as astrocytes play a number of active and neuron supporting roles in the brain. Toxicity on the astrocytes by amorphous silica generated in laboratory scale was compared to crystalline macro-sized silica using several doses to determine toxicological dose response curves. The cell viability experiments indicated that low particle doses of amorphous silica induced a small nonsignificant reduction in cell viability compared to crystalline silica which led to increased levels of toxicity. The gene expression of amyloid precursor protein (APP), a biomarker of neurodegenerative disease, was affected by particle exposure. Furthermore, particle exposure, in a dose-and time-dependent manner, affected the ability of the cells to communicate through gap junction channels. In conclusion, in vitro studies using low doses of particles are important to understand mechanisms of toxicity of occupational exposure to silica particles. However, these studies cannot be extrapolated to real exposure scenarios at work place, therefore, controlling and keeping the particle exposure levels low at the work place, would prevent potential negative health effects.

show abstract

“…88 However, the application of peptide vaccines is limited due to their unique peptide epitopes, low molecular weight, simple degradation and short half-life. 89,90 Nucleic acid vaccines are mainly divided into DNA vaccine and mRNA vaccine. 91 Nucleic acid vaccines offer greater advantages over peptide vaccines in terms of efficacy, reduced design and manufacturing time, and manufacturing scalability and reliability.…”

Section: Neoantigen Vaccinementioning

confidence: 99%

Personalised neoantigen‐based therapy in colorectal cancer

Zhu,

Li,

Chen

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

Colorectal cancer (CRC) has become one of the most common tumours with high morbidity, mortality and distinctive evolution mechanism. The neoantigens arising from the somatic mutations have become considerable treatment targets in the management of CRC. As cancer‐specific aberrant peptides, neoantigens can trigger the robust host immune response and exert anti‐tumour effects while minimising the emergence of adverse events commonly associated with alternative therapeutic regimens. In this review, we summarised the mechanism, generation, identification and prognostic significance of neoantigens, as well as therapeutic strategies challenges of neoantigen‐based therapy in CRC. The evidence suggests that the establishment of personalised neoantigen‐based therapy holds great promise as an effective treatment approach for patients with CRC.

show abstract

Cancer Immunotherapy: Comprehensive Mechanism Analysis of Mesoporous‐Silica‐Nanoparticle‐Induced Cancer Immunotherapy (Adv. Healthcare Mater. 10/2016)

Cited by 4 publications

References 0 publications

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Cellular Responses of Industrially Relevant Silica Dust on Human Glial Cells In Vitro

Personalised neoantigen‐based therapy in colorectal cancer

Contact Info

Product

Resources

About